📰 Acrx News
Acrx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acrx. Real-time updates on events, politics, business and more.
February 19, 2024
StockNews.com began coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Separately, HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of AcelRx Pharmaceuticals in a research report […]
January 26, 2024
StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note released on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock. Several other analysts have also recently commented on ACRX. Alliance Global Partners began coverage on AcelRx Pharmaceuticals in a report on Monday, October […]
January 17, 2024
StockNews.com started coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a report published on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock. Several other equities analysts have also recently commented on ACRX. HC Wainwright reaffirmed a buy rating and set a $5.00 price objective on shares […]
January 9, 2024
StockNews.com initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a report issued on Saturday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Several other analysts have also issued reports on the stock. HC Wainwright restated a buy rating and issued a $5.00 price objective on shares of […]
January 9, 2024
StockNews.com began coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. Several other brokerages also recently issued reports on ACRX. Alliance Global Partners started coverage on shares of AcelRx Pharmaceuticals in a report on […]
January 2, 2024
StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note released on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. A number of other research analysts also recently issued reports on the company. Alliance Global Partners initiated coverage on AcelRx Pharmaceuticals in a research […]
January 1, 2024
StockNews.com assumed coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note issued to investors on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock. ACRX has been the topic of a number of other reports. HC Wainwright reaffirmed a buy rating and set a $5.00 target […]
December 11, 2023
HC Wainwright reissued their buy rating on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Free Report) in a research note released on Thursday, Benzinga reports. They currently have a $5.00 price target on the specialty pharmaceutical company’s stock. Several other research firms have also weighed in on ACRX. Alliance Global Partners assumed coverage on shares of […]
November 1, 2023
AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link. AcelRx Pharmaceuticals (NASDAQ:ACRX – […]
October 7, 2023
Equities researchers at StockNews.com initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock. ACRX has been the topic of several other research reports. Alliance Global Partners assumed coverage on AcelRx Pharmaceuticals in a […]